术后辅助化疗起始时间影响乳腺癌患者的预后

美国MD Anderson癌症中心的de Melo Gagliato等于2014年第8期《Journal of Clinical Oncology》在线发表了题为《Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer》的论著，阐述了乳腺癌术后化疗起始时间对患者预后的影响。     

原发性乳腺淋巴瘤的手术治疗效果评估及淋巴结状况对治疗方案选择的重要性

William等最近在美国《外科学年鉴》2007年245卷第5期上发表了1篇题目为“Primary breast lymphoma：the role of mastectomy and the importance of lymph node status”的文章。     

2021年晚期结直肠癌治疗研究进展

结直肠癌是全球发病率第三的恶性肿瘤.目前晚期结直肠癌的治疗以化疗为基石.2021年美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)及欧洲肿瘤内科学(European Society of Medical Oncology,ESMO)公布了多项晚期结直肠癌免疫及靶向...     

更正

刊登于我刊2023年第2期第109页的《晚期胃癌二线治疗回顾性观察》一文, 作者张宇涛的单位信息中文更正为"山西省肿瘤医院、中国医学科学院肿瘤医院山西医院、山西医科大学附属肿瘤医院外科, 太原 030013";英文更正为"Department of Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013, China"。     

美国临床肿瘤学会／美国病理学家学会：2013年最新版HER-2检测指南

AntonioC．Wolff等在2013年31卷第31期的《Journal of Clinical Oncology》发表题为《Recommendationsforhumanepidermalgrowthfactorreceptor2testinginbreastcancer：AmericanSocietyofClinicalOncology／CollegeofAmericanPathologistsclinicalpracticeguidelineupdate》的论文。     

热烈祝贺《The Chinese-German Journal of Clinical Oncology》再获“第八届湖北省优秀期刊奖”

在2012年底湖北省新闻出版局、湖北省期刊协会共同举办的"第八届湖北省优秀期刊奖"评选活动中,经省刊协专业委员会初评、专家组复评和省评选领导小组审定,《The Chinese-German Journal of Clinical Oncology》再次荣获"第八届湖北省优秀期刊奖"。     

会议消息

TimeMay18--19,2006时间2006年5月18、19日Meeting10th International Paediatric Haematologyand Oncology Update Meeting会议第10届国际儿科血液学与肿瘤学新进展大会LocationRoyal College of Physicians of Edinburgh,Edinburgh,United Kingdom地址Royal College of Physicians of Edinburgh,Edinburgh,United Kingdom(英国爱丁堡)Tel+441794511331电话+441794511331Fax+441794511455传真+441794511455E-mailicms@dial.pipex.comE-mailicms@dial.pipex.comTi meAug24--25,2006时间2006年8月24、25日Meeting4th Annual In…     

不明原发灶骨转移癌的诊疗进展

正不明原发灶转移癌(cancer of unknown primary,CUP)是一类独立的转移性肿瘤的统称,组织学确诊为转移癌但检查后不能明确其原发解剖部位,约占人类所有新发癌症的3%~5%,是人类第7~8位常见的恶性肿瘤,也是第4位常见的致死性癌症~([1-3])。骨是CUP的第3好发部位,不明原发灶骨转移癌(bone metastases from cancer of unknown primary,BMCUP)是CUP中一种整体预后很差的类型,明确肿瘤的原发部位,有助于临床医生制订针对性的治疗方     

循证指南和决策支持服务在乳腺癌诊治过程中的作用

Patkar等在British Journal of Cancer（2006年第11期）中撰文介绍了循证指南和决策支持服务对可疑乳腺癌的三重鉴定的评估和讨论的有关内容，现摘录如下。     

持续他莫西芬辅助治疗10年比5年更能使ER阳性乳腺癌患者受益

Christina Davies等在2013年第381卷9869期的《The Lancet》发表题为《Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer： ATLAS,a randomised trial》的论著，研究结果显示：与5年相比，术后接受他莫昔芬（TAM）辅助治疗10年更能使ER阳性的乳腺癌患者受益。     

《肿瘤预防与治疗》文章荐读:2020年中国临床肿瘤学会《食管癌诊疗指南》解读

食管癌是常见的消化道肿瘤,其发病率在全球恶性肿瘤中排第7位,死亡率排第6位。中国是食管癌高发国家,每年新发病例约占全球的一半,其在男性的发病率和死亡率分别位于第5位和第4位。基于循证医学证据,结合我国食管癌特色,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)2019年在人民卫生出版社首次发表了《食管癌诊疗指南》(ISBN 978-7-117-28359-5)。     

紫杉醇脂质体联合顺铂及5-氟尿嘧啶治疗晚期胃癌的临床观察

目的 探讨紫杉醇脂质体联合小剂量顺铂及5-氟脲嘧啶(5-Fu)治疗晚期胃癌的近期疗效及安全性.方法 紫杉醇脂质体60 mg/m2,第1,8,15天,静滴;顺铂15 mg·m-2·d-1,第1～5天;5-Fu 500 mg·m-2·d-1,持续静脉泵入,第1～5天(共120 h);21 d为1个周期,2个周期后评价疗效和毒副反应.结果 60例晚期胃癌患者中,有59例患者可评价疗效.其中完全缓解(CR)3例,部分缓解(PR)29例,总有效率为54.2%,中位疾病进展时间(TTP)为7.1个月.40例初治患者中,CR 3例,PR 22例,总有效率为62.5%,中位TTp为7.6个月;20例复治患者中,19例患者可评价疗效,PR 7例,总有效率为36.8%,中位TTP为6.3个月.全组不良反应主要为血液学毒性及消化道反应,大部分为Ⅰ、Ⅱ度.结论 紫杉醇脂质体联合顺铂及5-Fu治疗晚期胃癌疗效肯定,特别对初治患者,不良反应轻,患者均能耐受,值得临床进行大样本研究.

Abstract：

Objective To evaluate the efficacy and toxicity of paclitaxel with low-dose cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma. Methods The patients were treated with paclitaxel liposome 60 mg/m2 I. V. Gtt on dl, 8, 15, DDP 15 mg · m-2 · D-1 by I. V. Gtt on dl -5, 5-Fu 500 mg · m -2 · d -1 by civ for 120 h, administered every 21 days. Results Out of the whole group, 3 cases achieved CR, 29 cases achieved PR with an ORR of 54.2% and median TTP of 7. 1 months. Out of 40 cases in the primary treatment, 3 cases achieved CR, 22 cases achieved PR with an ORR of 62.5% and median TTP of 7.6 months. Out of 20 evaluable retreated cases, no case achieved CR, 7 cases achieved PR with an ORR of 36. 8% and median TTP 6. 3 months. The main toxicities were hematological toxicities, nausea and vomiting of grade I - II. Conclusion The combination regimen of paclitaxel, lowdose cisplatin and 5-fluorouracil is effective and well tolerated for patients with advanced gastric carcinoma, especially for primary treatment cases. It is worthy of further study.     

激素疗法与乳腺癌

Franke等最近在2（1717年第2期《欧洲产科、妇科和生殖学杂志》上发表了题为“Breast cancer and cliinacteric complaints：weighing up risks of hormone therapy against quality of life”的文章。作者在阐述激素与乳腺癌发病风险后，进一步分析了激素治疗对于出现严重更年期症状的乳腺癌患者和有乳腺癌家族史患者可能带来的风险，最后为这些更年期综合征患者提出了治疗方式选择建议。     

《肿瘤国际组织学分类》中译本征订

由浙江省肿瘤防治办公室组织翻译出版的WHO《肿瘤国际组织学分类》(International Histological Classification of Tumours)第11—25分册以及第1—2分册合订本(中译本)已与读者见面。该书系肿瘤防治研究工作的重要参考书,图文并茂,十分难得,全书共1288页,插图1960张。     

2012年美国临床肿瘤学会年会——小细胞肺癌治疗研究进展

第48届美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)年会于2012年6月1日-5日在美国芝加哥召开,现就本次大会关于小细胞肺癌(small cell lung cancer,SCLC)治疗的研究进展作一介绍.     

第七届亚洲临床肿瘤学大会暨第九届全国临床肿瘤学大会征文通知

由亚洲临床肿瘤学会（Asia Clinical Oncology Society，ACOS）、中国抗癌协会临床肿瘤学协作专业委员会（Chinese Society of Clinical Oncology，CSCO）和国家卫生部全国肿瘤防治研究办公室联合主办，中国医学论坛报社、临床肿瘤学杂志社和北京希思科临床肿瘤学研究基金会共同协办的第七届亚洲临床肿瘤学大会暨第九届全国临床肿瘤学大会，定于2006年9月14日-18日在北京举行。     

瘦素受体基因变异与乳腺癌发生的关系

目的 探讨瘦素受体基因(OB-R)第exon 4、6、9、20核苷酸位点变异与乳腺癌发生的关系.方法 采用体外基因扩增、测序的方法,检测155例乳腺癌患者肿瘤组织、56例乳腺良性病组织和100例健康人的抗凝血中OB-R基因核苷酸位点变异情况.结果 OB-R基因第exon 4在乳腺癌组、乳腺良性病组和健康对照组受检者中均未发生核苷酸位点变异,而第exon 9的1029核苷酸位点均发生了碱基置换,3组之间比较,差异无统计学意义(P=0.574).第exon 6的668核苷酸位点发生了碱基颠换,导致多态性Gln223Arg.Gln223Arg的GG、GA、AA基因型在乳腺癌组中的表达频率分别为70.9%、17.4%和12.3%,在乳腺良性病组中的表达频率分别为80.4%、14.3%和5.4%,在健康对照组中的表达频率分别为81.0%、16.0%和3.0%;G和A等位基因在乳腺癌组中的表达频率分别为79.1%和20.8%,在乳腺良性病组中的表达频率分别为87.5%和12.5%,在健康对照组中的表达频率分别为89.0%和11.0%.3组Gln223Arg基因型和等位基因表达频率比较,差异有统计学意义(x2=16.11,P＜0.005;x2=11.41,P＜0.01).第exor 20的3057核苷酸位点发生了碱基颠换,导致多态性Pro1019Pro.Pro1019Pro的GG、GA、AA基因型在乳腺癌组中的表达频率分别为11.6%、30.3%和56.1%,在乳腺良性病组中的表达频率分别为32.1%、44.0%和28.5%,在健康对照组中的表达频率分别为32.0%、45.0%和23.0%;G和A等位基因在乳腺癌组中的表达频率分别为26.8%和73.2%,在乳腺良性病组中的表达频率分别为51.8%和48.2%,在健康对照组中的表达频率分别为54.5%和45.5%.3组Pro1019Pro基因型和等位基因变异频率比较,差异有统计学意义(x2=6.56,P＜0.03;x2=5.45,P＜0.05).乳腺癌组超重和肥胖者第exon 6、exon 20发生碱基颠换的频率明显高于正常体重者,差异有统计学意义(P＜0.05,P＜0.01).结论 OB-R基因第exon9核苷酸位点变异与乳腺癌发生无关,而第exon 6和第exon 20核苷酸位点变异可能与乳腺癌的发生风险有关.

Abstract：

Objective The aim of this study was to investigate the relationship of the mutations of leptin receptor gene exon 4, exon 6, exon9, and exon20 with the tumorigenesis of breast cancer. Methods Genomic DNA was extracted from breast cancer tissues of 155 patients, benign lesions of 56 patients and normal tissues and blood samples from 100 health control subjects. The leptin receptor genes were assayed with polymerase chain reaction (PCR) amplification and direct sequence analysis. Results Nucleotide substitutions no mutations were found at exon 4, and nucleotide substitutions occurred at codon 1029 in exon 9, no significant difference among the three groups (P =0.574). The nucleotide substitutions at codon 668 in exon 6 resulted in Gln223Arg polymorphisms. The occurring frequencies of GG, GA, AA in breast cancer, breast benign lesions tissues and health tissues control group were 70.9% and 17.4%, 12.3%;80.4%, 14.3% and 5.4%; and 81.0%, 16.0%, and 3.0%, respectively. Alleles of G and A in the three groups were 79.1% and 20.8%, 87.5% and12.5%, and 89.0% and 11.0%, respectively. Compared the Gln223Arg genotype with the three allele groups, there were significant differences (x2 = 16. 11 ,P ＜0.005 and x2 = 11.41, P ＜ 0. 01 ), respectively. The nucleotide substitutions at codon 3057 in exon 20 resulted in Pro1019Pro polymorphisms. The occurrence frequencies of GG, GA, AA in the breast cancer,benign disease and health control groups were 11.6%, 30.3% and 56. 1%; 32.1%, 44.0% and 28.5%;and 32.0%, 45.0% And 23.0%, respectively. Alleles of G and A in the three groups were 26.8% and 73.2% ,51.8% and 48.2%, and 54.5% and 45.5%, respectively. There are significant differences among the three groups (x2 = 6.56, P ＜ 0. 03 and x2 = 5.45, P ＜ 0. 05 ), respectively. Nucleotide substitutions occurred at relatively high frequencies at exon 6 and exon 20 in obese and overweight breast cancer patients compared with those in normal weight breast cancer patients, there were significant differences ( P ＜ 0.05and P＜0.01). Conclusions Our findings show that there is no relationship between the variations of leptin receptor gene exon 9 and tumorigenesis of breast cancer. The variation rate of leptin receptor gene exon 6 and exon 20 are significantly increased in the obese and overweight breast cancer paztients.     

阿那曲唑对绝经后乳腺癌患者血脂的影响

目的 观察阿那曲唑辅助治疗对中国绝经后乳腺癌患者血脂代谢的影响及其他不良反应.方法 需要术后辅助内分泌治疗的绝经后乳腺癌患者285例,给予阿那曲唑1 mg,1次/d,分别检测其服药前及服药后3个月、6个月、1年、2年、3年、4年和5年的总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)水平.电话随访服药过程中出现的其他不良反应.结果 285例患者的中位服药时间为3.6年.服药6个月后即导致LDL-C升高,持续至服药后第5年,其中服药后第4年最高,为(3.64±0.96)mmol/L,较服药前[(3.08±0.90)mmol/L]升高18.2%.服药1年后,TC和HDL-C开始升高,并持续至服药后第4年,TG无明显变化.亚组分析显示,对于服药前伴有高血脂的患者,除服药后1年出现TC升高(随后恢复)外,阿那曲唑对高血脂患者的血脂无明显影响;相对于＜60岁的患者,阿那曲唑对于年龄≥60岁患者的血脂影响更明显.服药过程中出现的其他不良反应包括潮热、骨关节疼痛、烦躁、恶心呕吐、腹泻、乏力、阴道干燥、体重增加、阴道出血、骨折、皮疹等,均较轻微,患者可耐受.结论 绝经后乳腺癌患者术后接受阿那曲唑辅助内分泌治疗,可导致血脂代谢的变化,主要表现为TC、LDL-C、HDL-C升高,尤其对于年龄≥60岁的患者影响更加明显.建议长期口服阿那曲唑的患者定期复查血脂.其他不良反应轻微,患者可耐受.

Abstract：

Objective The aim of this study was to evaluate the effect of anastrozole, a new generation aromatase inhibitor, on the lipid metabolism in postmenopausal Chinese women with early breast cancer, and observe the adverse reactions as well. Methods Postmenopausal women with early breast cancer patients took anastrozole 1 mg per day. The lipid profiles of total cholesterol, triglyceride, low density lipoprotein, and high density lipoprotein were assessed before taking the drug, 3 months, 6 months after taking medication, and later once a year, until the end of medication or follow-up. Patients taking lipid-lowering drugs were excluded. The adverse reactions during the process of taking medication was followed-up by telephone. Results Two hundred and eighty-five postmenopausal breast cancer patients took part in the trial from Jan. 2003 to Jun. 2009. All patients had completed primary surgery and demonstrated a postmenopausal status. ER or PR positivity was confirmed by histopathology. Taking the medication from a minimum of one year to a maximum of 5 years,with a median time of 3.61 years. During the medication time, anastrozole significantly increased the levels of low density lipoprotein-cholesterol after 6 months of treatment, continueing to 5 years, from (3.08±0.90)mmol/L to (3.59±0.59)mmol/L,with a maximal increase of 18.2% higher than that before medication. Anastrozole significantly increased the levels of total cholesterol and high density lipoprotein-cholesterol after 1 years of treatment. Anastrozole significantly reduced the levels of triglycerides after 1 years of treatment. Anastrozole showed no significant effect on serum lipids in the patients with pre-existing hyperlipidemia. A more significant effect on blood lipids was observed in patients aged ≥ 60-years than that in patients less than 60 years of age. The rate of other adverse events were similar to that reported in foreign patients. Conclusions For the postmenopausal patients with breast cancer, taking anastrozole may lead to an abnormal lipid metabolism. Anastrozole significantly increases the levels of low density lipoprotein-cholesterol, total cholesterol and high density lipoprotein-cholesterol, and significantly reduces the level of triglycerides. The rate of other adverse events were similar to that reported in foreign patients. it is suggested that the blood lipid levels should be regularly assessed in patients with long-term anastrozole treatment. The rate of other adverse events similar to that reported with foreign patients, and patients tolerate this treatment well.     

调强放疗联合培美曲塞和顺铂同期化疗局部晚期非小细胞肺癌的临床研究

目的 探讨调强放疗结合培美曲赛和顺铂同期化疗局部晚期非小细胞肺癌的疗效及副反应.方法 42例Ⅲ期非小细胞肺癌患者(ⅢA期25例,ⅢB期17例)接受DT66 Cy调强放疗,疗中给予培美曲塞500 mg/m2静脉滴注第1天,顺铂75 mg/m2静脉滴注第1天,21 d为1个周期,共4个周期.放化疗在同大开始进行,先化疗后放疗.2例放疗总量54 Gy,2例56 Gy;3例完成了2周化疗,1例完成了 3周化疗.结果 34例患者完成了治疗计划.全组总有效率为79%,1年总生存率为65%.≥3级骨髓抑制2例,3级放射性食管炎3例,≥2级放射性肺炎4例,3级黏膜炎1例.结论 培美曲赛和顺铂同期放化疗局部晚期非小细胞肺癌患者具有较好的近期疗效,副反应可耐受.

Abstract：

Objective To observe the therapeutic effect and toxicity of chemoradiation of locally advanced non-small cell lung cancer by intensity modulated irradiation combined with pemetrexed and cisplatin. Methods Fourty-two patients presented with Ⅲ - stage non-small cell lung cancer(Ⅲ、 25 patients, ⅢB 17 patients)received concurrent chemoradiotherapy. Intensity modulated irradiation technique was used to the total dose of 66 Gy and concurrent chemotherapy consisted of pemetrexed 500 mg/m2 on Day 1 and cisplatin 75 mg/m2 on Day 1 by intravenous infusion once every 3 weeks at the initiation of radiation.Patients received 4 cycles of chemotherapy. Results Thirty-four patients finished the whole of therapeutic schedule. And 2 patients received radiation with total dose of 54 Gy, 2 patients 56 Gy;3 patients received 2 cycles of chemotherapy, 1 patients 3 cycles of chemotherapy. Total effective rate was 79%. There were 2 patients with ≥3 grade marrow depression, 3 patients with 3 grade radiation esophagitis, 4 patients with ≥2 radiation pneumonitis, and 1 patient with 3 grade mucositis. The 1-year survival rate was 65%.Conclusion Recent effect was favourable and toxicity was tolerable for chemoradiation of locally advanced non-small cell lung cancer by intensity modulated irradiation combined with pemetrexed and cisplatin.     

国际抗癌联盟出版介绍世界各国癌症机构的新书

由国际抗癌联盟国际协作活动委员会主持编辑出版了《国际专业性癌症研究与治疗机构概览》(《Inter-national Directory of Specialized Cancer Reseachand Treatment Establishments》)的第二版,列为“国际抗癌联盟技术报告丛书”第33卷。